According to a recent study, anti-PD-L1 target therapy could act on those subgroups of PitNETs characterized by elevated Ki-67 and p53 values, with a higher percentage of tumor-infiltrating CD68+ macrophages and CD8+ TILs [46]. This evidence concerns the gene CD274 and neoplasm.